SKIP TO CONTENT
30+/SKIN
← ACTIVESRECORD A-16FAMILY ORGANIC PEROXIDE — OXIDISING ANTIMICROBIAL

Benzoyl Peroxide

Benzoyl peroxide

The standard cause of topical intolerance, and — sealed inside silica microcapsules — the second most effective rosacea treatment in this register. The molecule did not change.

THE TRIALLED STRENGTH, IN THE RANGE WE HAVE SEEN2.5% ——— 10%
5%

The marker is the strength the trials were actually run at. The bar is the span this register has recorded, approved and compounded together. Anything below the marker is a dose nobody has tested; anything above it is an assumption about a dose–response curve nobody has drawn.

IDENTITY & RATINGSA
INCIBenzoyl peroxide
FAMILYOrganic peroxide — oxidising antimicrobial
MOL. WEIGHT242.23 g/mol
REFERENCE CONC.5%
RANGE SEEN2.5 – 10%
STATUSNON-PRESCRIPTION
ACTS ATEPIDERMIS
ONSET4–12 WK
STABILITYOXIDISER — AIRLESS PUMP; BLEACHES FABRIC
TRIALS ON FILE1
IRRITATION INDEX2 / 10
STRATUM CORNEUMEPIDERMISDERMIS

The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.

01

Mechanism

EVIDENCE GRADE A

An oxidising agent with bactericidal and keratolytic effects. It does not select for bacterial resistance, which is why it is conventionally paired with topical antibiotics. The label of the approved rosacea product states that the precise mechanism in rosacea is unknown.

HOUSE NOTES

  • Conventional 5% benzoyl peroxide would not be used on rosacea skin. Microencapsulated 5% produced application-site pain in 2% of subjects and treatment success of 47.4% and 49.2%.
  • It is available over the counter at the same concentration. That product is not this product, and substituting it to save money defeats the entire design.
  • One of the few antimicrobials that does not select for resistance, which is why it is the standard partner for topical clindamycin.
  • It bleaches towels, pillowcases and collars regardless of how it is delivered.

MEASURED ENDPOINTS

IGA treatment success, rosacea+26.7%
12 WKREF-27

SUPPORTING RECORDS

  • Multicentre randomised, vehicle-controlled; treatment difference 26.7% (95% CI 16.7–36.8); mean subject age 51

    N=361 · 12 WK · DOUBLE-BLIND

02

Layering

CONFLICTS & PAIRINGS
DO NOT LAYER
  • Fabric — it bleaches
  • Concurrent application with tretinoin
PAIRS WITH
  • Topical antibiotics, to limit resistance
  • Retinoids, at a different time of day
03

Reviewed in

1 REVIEW
EVERY FIGURE HERE RESOLVES TO A RECORD IN THE EVIDENCE REGISTER. NOT MEDICAL ADVICE.
THE DRAW · NO. 01

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm plan — the compounded, physician-reviewed subscription we take apart in the register. Worth $780. Leave an address and you are entered.

PRIZE
12 MONTHS OF COREAGE RX
VALUE
$780 — $64.99/MO × 12
ENTRY
ONE EMAIL ADDRESS

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.

DEPTH 000%
THE DRAW · ONE READER

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm subscription — compounded, physician-reviewed, delivered. The plan we score in the register.

VALUE$780
TERM12 MONTHS$64.99/MO × 12

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.